ALK and non-small cell lung carcinoma: The epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) are the most clinically relevant oncogenic drivers in NSCLC (Gaughan and Cost, 2011; Levy et al., 2012).